Biotech Company Polypid Aims to Raise $75 Million with Nasdaq IPO
The Israel-based company develops a pharmaceutical mechanism that slows down drug delivery
For daily updates, subscribe to our newsletter by clicking here.
Based on the prospectus, Polypid is looking to raise the money according to a pre-funding valuation of $275 million to $325 million.
Nasdaq. Photo: Getty Images
Established in 2008 and based in Petach Tikva, a city in the Tel Aviv metropolitan area, Polypid is a clinical-stage company developing encapsulation technology for extended release, localized drug delivery. The technology could enable better control of problematic drugs like those that are sensitive to heat or pH levels or are toxic in large doses, improving both their safety and their performance.
The company intends to use the funding raised for clinical development and trials, and for manufacturing activities, according to the prospectus.
- Controlled Drug Release Company Polypid Attempts Second Nasdaq IPO
- Drug Conduction Company Prepares for Nasdaq IPO
- Five Israeli Companies Are Planning IPOs in 2018, Says Nasdaq President
This is Polypid’s second IPO attempt. The company first tried listing three years ago at a valuation of $100 million, but withdrew its submission in early 2015. Polypid previously raised $22 million in 2016 at a $82 million valuation.
Goldman Sachs, Oppenheimer & Co., Cowen Inc., Cantor Fitzgerald & Co. and Raymond James Financial are the underwriters listed for the IPO. Polypid stated they have the option to purchase up to 500,000 additional ordinary shares at the initial price.
